Literature DB >> 28320182

Axial MR diffusion tensor imaging and tractography in clinical diagnosed and pathology confirmed cervical spinal cord astrocytoma.

Mangsuo Zhao1, Bingxin Shi1, Tuoyu Chen2, Yuqi Zhang2, Tongchao Geng1, Liyan Qiao1, Mingjie Zhang3, Le He4, Huancong Zuo5, Guihuai Wang6.   

Abstract

OBJECTIVE: To evaluate the diffusion tensor imaging (DTI) and diffusion tensor tractography (DTT) features of cervical spinal cord astrocytoma.
METHODS: Eleven patients with cervical spinal cord astrocytomas and 10 healthy volunteers were recruited in this study. Conventional magnetic resonance imaging (MRI) and axial DTI were performed on a 3.0T MRI system. Apparent diffusion coefficient (ADC), fractional anisotropy (FA), axial diffusivity (AD), and radial diffusivity (RD) values for the lesions were measured. DTT was performed using the principal diffusion direction method.
RESULTS: ADC values of the lesions and the normal-appearing tissue around the tumour (NATAT) on T2-weighted imaging (T2WI) increased. The ADC values of the lesions were higher. The FA values of the lesions and the NATAT decreased significantly, with the lesions having lower FA values. The RD value (1.36±0.49) of the tumours was significantly higher than those found in the healthy controls, but similar for the AD value (1.84±0.56). There were no differences in ADC or FA values between lesions and NATAT in McCormick Type I vs. Type II patients. Based on the DTT, 7 patients with solid mass tumours were classified as Type I. One patient with a solid mass, 2 patients with cystic degeneration inside the lesions, and 1 patient with a cyst around the mass were classified as Type II.
CONCLUSIONS: FA values of the cervical spinal cord astrocytoma decreased, but the ADC values increased. DTI was sensitive for the evaluation of pathological changes that could not be visualized on T2WI. Our preliminary study indicates that DTT can be used to guide operation planning, and that axial images of DTT may be more valuable.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Astrocytoma; Cervical spinal cord; Diffusion tensor imaging; Diffusion tensor tractography

Mesh:

Year:  2017        PMID: 28320182     DOI: 10.1016/j.jns.2017.01.044

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  6 in total

1.  Diffusion tensor imaging in unclear intramedullary tumor-suspected lesions allows separating tumors from inflammation.

Authors:  Marc Hohenhaus; Yorn Merz; Jan-Helge Klingler; Christoph Scholz; Ulrich Hubbe; Jürgen Beck; Katharina Wolf; Karl Egger; Marco Reisert; Nico Kremers
Journal:  Spinal Cord       Date:  2021-12-30       Impact factor: 2.473

Review 2.  Primary Spinal Astrocytomas: A Literature Review.

Authors:  John Ogunlade; James G Wiginton; Christopher Elia; Tiffany Odell; Sanjay C Rao
Journal:  Cureus       Date:  2019-07-26

3.  Sodium Fluorescein for Spinal Intradural Tumors.

Authors:  Semih Kivanc Olguner; Ali Arslan; Vedat Açık; İsmail İstemen; Mehmet Can; Yurdal Gezercan; Ali İhsan Ökten
Journal:  Front Oncol       Date:  2021-01-28       Impact factor: 6.244

4.  Intraoperative Computed Tomography-Based Navigation with Augmented Reality for Lateral Approaches to the Spine.

Authors:  Mirza Pojskić; Miriam Bopp; Benjamin Saß; Andreas Kirschbaum; Christopher Nimsky; Barbara Carl
Journal:  Brain Sci       Date:  2021-05-15

Review 5.  MICROSURGICAL MANAGEMENT OF LOW-GRADE SPINAL CORD ASTROCYTOMA IN ADULTS: A PERSONAL CASE SERIES REPORT AND BRIEF LITERATURE REVIEW.

Authors:  Mirza Pojskić; Krešimir Rotim; Bruno Splavski; Kenan I Arnautović
Journal:  Acta Clin Croat       Date:  2020-09       Impact factor: 0.780

6.  Role of Diffusion Tensor Imaging Parameters in the Characterization and Differentiation of Infiltrating and Non-Infiltrating Spinal Cord Tumors : Preliminary Study.

Authors:  Edyta Maj; Barbara Szemplińska; Wojciech Szeszkowski; Marek Prokopienko; Andrzej Cieszanowski; Andrzej Marchel; Olgierd Rowiński
Journal:  Clin Neuroradiol       Date:  2019-11-21       Impact factor: 3.649

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.